Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study

Increased Penicillin Nonsusceptibility of Nonvaccine-Serotype Invasive Pneumococci Other than Serotypes 19A and 6A in Post-7-Valent Conjugate Vaccine Era

(2011) Robert E. Gertz et al.   JOURNAL OF INFECTIOUS DISEASES

Affinity of Ceftaroline and Other  -Lactams for Penicillin-Binding Proteins from Staphylococcus aureus and Streptococcus pneumoniae

(2010) K. Kosowska-Shick et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Ceftaroline against 623 Diverse Strains of Anaerobic Bacteria

(2010) D. M. Citron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Ceftaroline on Normal Human Intestinal Microflora

(2010) G. Panagiotidis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Ceftaroline against Recent Emerging Serotypes of Streptococcus pneumoniae in the United States

(2010) M. R. Jacobs et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Microbial Etiologies of Hospital‐Acquired Bacterial Pneumonia and Ventilator‐Associated Bacterial Pneumonia

(2010) Ronald N. Jones   CLINICAL INFECTIOUS DISEASES

Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998–2009)

(2010) Ronald N. Jones et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia

(2010) Ronald N. Jones et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

AmpC induction by ceftaroline

(2010) S. Mushtaq et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

(2010) M. H. Wilcox et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

(2010) G. R. Corey et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study

(2010) R. N. Jones et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae

(2010) H. Moisan et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparative Pharmacokinetics of Ceftaroline in Rats, Rabbits, and Monkeys following a Single Intravenous or Intramuscular Injection

(2009) Y. Ge et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Ceftaroline Alone and in Combination against Clinical Isolates of Resistant Gram-Negative Pathogens, Including  -Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa

(2009) C. Vidaillac et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vivo Activity of a Novel Anti-Methicillin-Resistant Staphylococcus aureus Cephalosporin, Ceftaroline, against Vancomycin-Susceptible and -Resistant Enterococcus faecalis Strains in a Rabbit Endocarditis Model: a Comparative Study with Linezolid and Vancomycin

(2009) C. Jacqueline et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

POST-ANTIBIOTIC EFFECT OF CEFTAROLINE AGAINST GRAM-POSITIVE ORGANISMS

(2009) G. A. PANKUCH et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Ceftaroline against Methicillin-Resistant Staphylococcus aureus and Heterogeneous Vancomycin-Intermediate S. aureus in a Hollow Fiber Model

(2009) C. Vidaillac et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Infectious Disease Hospitalizations in the United States

(2009) Krista L. Yorita Christensen et al.   CLINICAL INFECTIOUS DISEASES

Rationale for Revised Penicillin Susceptibility Breakpoints versusStreptococcus pneumoniae:Coping with Antimicrobial Susceptibility in an Era of Resistance

(2009) Melvin P. Weinstein et al.   CLINICAL INFECTIOUS DISEASES

Ceftaroline

(2009) George G. Zhanel et al.   DRUGS

Ceftaroline: a cephalosporin with expanded Gram-positive activity

(2009) Zeina A Kanafani et al.   Future Microbiology

Newer Beta-lactam Antibiotics: Doripenem, Ceftobiprole, Ceftaroline, and Cefepime

(2009) Jose A. Bazan et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia

(2009) Ian Morrissey et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008

(2009) S. N. Patel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid

(2009) R. E. Mendes et al.   JOURNAL OF CLINICAL MICROBIOLOGY

In Vitro Evaluation of the Antimicrobial Activity of Ceftaroline against Cephalosporin-Resistant Isolates of Streptococcus pneumoniae

(2008) L. McGee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Ceftaroline against Streptococcus pneumoniae Isolates Exhibiting Resistance to Penicillin, Amoxicillin, and Cefotaxime

(2008) A. Fenoll et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Antimicrobial Activity of a New Cephalosporin, Ceftaroline, and Determination of Quality Control Ranges for MIC Testing

(2008) S. D. Brown et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Profiling of Ceftaroline against a Collection of Recent Bacterial Clinical Isolates from across the United States

(2008) Y. Ge et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Activities of Ceftaroline and ME1036 Tested against Clinical Strains of Community-Acquired Methicillin-Resistant Staphylococcus aureus

(2008) H. S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Stability and Stabilization Studies of TAK-599 (Ceftaroline Fosamil), a Novel N-Phosphono Type Prodrug of Anti-methicillin Resistant Staphylococcus aureus Cephalosporin T-91825

(2008) Yukihiro Ikeda et al.   CHEMICAL & PHARMACEUTICAL BULLETIN

Clinical Trial Design for Mild‐to‐Moderate Community‐Acquired Pneumonia—An Industry Perspective

(2008) Roger M. Echols et al.   CLINICAL INFECTIOUS DISEASES

Executive Summary: Workshop on Issues in the Design and Conduct of Clinical Trials of Antibacterial Drugs in the Treatment of Community‐Acquired Pneumonia

(2008) Brad Spellberg et al.   CLINICAL INFECTIOUS DISEASES

Population Snapshot of EmergentStreptococcus pneumoniaeSerotype 19A in the United States, 2005

(2008) Matthew R. Moore et al.   JOURNAL OF INFECTIOUS DISEASES

Serotype Replacement and Multiple Resistance in Streptococcus pneumoniae After the Introduction of the Conjugate Pneumococcal Vaccine

(2008) Robertino Mera et al.   Microbial Drug Resistance